Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2021 - 2026)

Zentalis Pharmaceuticals has reported Non-Current Assets over the past 6 years, most recently at $35.0 million for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 15.0% year-over-year to $35.0 million; the TTM value through Mar 2026 reached $149.8 million, down 20.26%, while the annual FY2025 figure was $35.8 million, 19.19% down from the prior year.
  • Non-Current Assets for Q1 2026 was $35.0 million at Zentalis Pharmaceuticals, down from $35.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $104.4 million in Q1 2022 and troughed at $35.0 million in Q1 2026.
  • A 5-year average of $60.5 million and a median of $53.7 million in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: crashed 42.62% in 2023 and later decreased 9.48% in 2024.
  • Year by year, Non-Current Assets stood at $87.4 million in 2022, then tumbled by 37.09% to $55.0 million in 2023, then decreased by 19.46% to $44.3 million in 2024, then decreased by 19.19% to $35.8 million in 2025, then fell by 2.25% to $35.0 million in 2026.
  • Business Quant data shows Non-Current Assets for ZNTL at $35.0 million in Q1 2026, $35.8 million in Q4 2025, and $38.9 million in Q3 2025.